SCHEMBL25375435

SCHEMBL25375435

CNCc1ccc(C(F)(F)F)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.55
HTR2A P28223 6/20 0.55
KCNH2 Q12809 6/20 0.55
SLC6A2 P23975 2/20 0.47
SLC6A3 Q01959 1/20 0.47
DAO P14920 1/20 0.44
MPO P05164 1/20 0.41
TPO P07202 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
IDO1 P14902 1/20 0.39
EPHX2 P34913 1/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
KIF11 P52732 1/20 0.37
RAPGEF4 Q8WZA2 1/20 0.37
PDE2A O00408 1/20 0.37
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25375857 0.85 SLC6A4 (0.42) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL9120134 0.83 IDO1 (0.53) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL21446971 0.83 SLC6A4 (0.52) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL25376437 0.81 DAO (0.42) SLC6A4HTR2AKCNH2DAORXRA
SCHEMBL13840653 0.79 SLC6A4 (0.54) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL5325645 0.79 SLC6A4 (0.54) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL31137133 0.79 SLC6A4 (0.63) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL4244859 0.78 SLC6A4 (0.63) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL17670630 0.78 SLC6A4 (0.52) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL21945440 0.78 DAO (0.47) SLC6A4HTR2AKCNH2DAOMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 SLC6A4 4401/4885HTR2A 1255/4885KCNH2 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.